NVO
Novo Nordisk A/S
37.50$
+0.6%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 35.7% | 35.5% | 43.2% | 36.9% | 39.9% | 38.3% | 40.9% | 39.1% | 44.6% | 46.9% | 41.7% | 38.5% | |
| 3.9% | 2.7% | 2.9% | 2.8% | 3.5% | 4.6% | 4.5% | 4.3% | 4.2% | 4.1% | 6.6% | 7.1% | |
| 0.4% | 0.4% | 0.3% | 0.3% | 0.4% | 0.3% | 0.6% | 0.7% | 0.9% | 0.9% | 0.8% | – | |
| 4.4% | 0.0% | 9.8% | 3.1% | 4.9% | 5.5% | 7.0% | 7.5% | 12.5% | – | – | – | |
| -2.4% | -2.0% | -3.3% | -3.3% | -3.0% | -2.8% | -3.4% | -6.1% | -3.0% | -5.3% | 0.9% | 1.2% | |
| 4.9% | 5.9% | 7.4% | 7.7% | 11.1% | 9.2% | 17.4% | 5.2% | 8.3% | 16.7% | 17.7% | 29.2% | |
| -2.3% | -5.7% | -6.1% | -5.9% | -10.8% | -9.4% | -17.7% | -22.4% | -14.1% | -18.9% | -44.4% | -25.6% | |
| 13.4% | 12.0% | 21.3% | 16.9% | 17.0% | 15.9% | 15.9% | 15.3% | 14.3% | 13.7% | 15.2% | 16.7% | |
| -16.5% | -15.9% | -13.5% | -15.1% | -13.9% | -12.6% | -13.3% | -13.8% | -13.6% | -12.9% | -6.9% | -0.4% | |
| – | 0.0% | 0.1% | 0.1% | 0.1% | -0.6% | 3.7% | 11.0% | -1.4% | -0.6% | 25.2% | 8.0% | |
| -29.9% | -27.9% | -34.8% | -32.0% | -30.9% | -29.1% | -25.4% | -18.1% | -29.3% | -27.2% | 3.0% | -9.2% | |
| 3.6% | 2.0% | 2.3% | -1.2% | -1.4% | -0.2% | -2.5% | -1.1% | 1.1% | 0.7% | 0.4% | 3.5% | |
| 30.8% | 29.5% | 35.8% | 29.1% | 28.8% | 29.1% | 23.5% | 33.8% | 36.2% | 30.1% | 24.0% | 9.4% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.